Attauabi M, Hoglund C, Fassov J, Pedersen KB, et al. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-1048.
PMID: 34224299